Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169271 · ClinicalTrials.gov registry record · Phase 2
Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT02169271: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02169271 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02169271, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This randomized phase II trial studies acetylsalicylic acid compared to placebo in treating high-risk patients with subsolid lung nodules. A nodule is a growth or lump that may be malignant (cancer) or benign (not cancer). Chemoprevention is the use of drugs to keep cancer from forming or coming back. The use of acetylsalicylic acid may keep cancer from forming in patients with subsolid lung nodules.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2014-11-21 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02169271
The ClinicalTrials.gov registry entry for NCT02169271 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02169271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02169271 about?
NCT02169271 is a clinical study titled "Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules". This randomized phase II trial studies acetylsalicylic acid compared to placebo in treating high-risk patients with subsolid lung nodules. A nodule is a growth or lump that may be malignant (cancer) or benign (not cancer). Chemoprevention is the use of drugs to keep cancer from forming or coming bac...
What is the current status of trial NCT02169271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2014-11-21. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT02169271?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Aspirin (DRUG).
Who is sponsoring clinical trial NCT02169271?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.